These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20570957)

  • 1. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
    O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
    Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
    Syrigos KN; Sitara D; Georgiou E; Harrington KJ
    Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors.
    Ceppi P; Volante M; Ferrero A; Righi L; Rapa I; Rosas R; Berruti A; Dogliotti L; Scagliotti GV; Papotti M
    Clin Cancer Res; 2008 Feb; 14(4):1059-64. PubMed ID: 18281538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
    Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
    Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
    Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
    Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
    Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
    Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
    Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
    Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.